← Back to patent-cliff list
阿地溴铵
Tier C — Watch / tradeAclidinium Bromide
Almirall Sa
Originator
2012
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：CHRM3
Brand：Tudorza Pressair、Eklira、Tudorza/Eklira、TudorzaGenuair、Tudorza、Eklira Genuair、Bretaris Genuair
Indications (approved)：慢性阻塞性肺疾病
Regional status
US
批准上市
2012-07-23
EU
批准上市
2012-07-20
China
批准上市
2024-08-05
Japan
批准上市
2015-03-26
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Aclidinium Bromide?
Approved indications include: 慢性阻塞性肺疾病.
When does the Aclidinium Bromide patent expire?
No public expiry year is available for Aclidinium Bromide yet; this page updates once verified.
How do I get a quote for Aclidinium Bromide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-25